We narrowed to 1,090 results for: aav

#22222-AAV9

Ready-to-use AAV9 particles produced from AAV-FLEX-Arch-GFP (#22222). In addition to the viral particles, you will also receive purified AAV-FLEX-Arch-GFP plasmid DNA. CAG-driven cre-dependent Arch-GFP expression for optogenetic neural inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chow et al Nature. 2010 Jan 7. 463(7277):98-102.

Feb. 20, 2018

Academic Institutions and Nonprofits only

#159605-AAV9

Ready-to-use AAV9 particles produced from pAAV-CAG-NIR-GECO2G (#159605). In addition to the viral particles, you will also receive purified pAAV-CAG-NIR-GECO2G plasmid DNA. CAG-driven expression of the near-infrared calcium indicator NIR-GECO2G. These AAV preparations are suitable purity for injection into animals.

Robert Campbell

Qian et al PLoS Biol. 2020 Nov 24;18(11):e3000965.

Dec. 18, 2024

Academic Institutions and Nonprofits only

#50476-AAV1

Ready-to-use AAV1 particles produced from pAAV-CaMKIIa-hM3D(Gq)-mCherry (#50476). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hM3D(Gq)-mCherry plasmid DNA. CaMKIIa-driven hM3D(Gq) receptor with an mCherry reporter for CNO-induced neuronal activation. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Jan. 8, 2025

Academic Institutions and Nonprofits only

#20071-AAV1

Ready-to-use AAV1 particles produced from pACAGW-ChR2-Venus-AAV (#20071). In addition to the viral particles, you will also receive purified pACAGW-ChR2-Venus-AAV plasmid DNA. CAG-driven, channelrhodopsin fused to Venus for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karel Svoboda

Leopoldo et al Nature. 2009 Jan 18.

Feb. 21, 2018

Academic Institutions and Nonprofits only

#176753-AAV1

Ready-to-use AAV1 particles produced from AAV-mDlx-jGCaMP8f-WPRE (#176753). In addition to the viral particles, you will also receive purified AAV-mDlx-jGCaMP8f-WPRE plasmid DNA. mDlx-driven expression of ultrafast calcium sensor GCaMP8f. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Feb. 24, 2023

Academic Institutions and Nonprofits only

#105678-AAV5

Ready-to-use AAV5 particles produced from pAAV_hSyn1-SIO-stGtACR1-FusionRed (#105678). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR1-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

Sept. 24, 2020

Academic Institutions and Nonprofits only

#99133-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-fDIO-mNeonGreen (#99133). In addition to the viral particles, you will also receive purified pAAV-CAG-fDIO-mNeonGreen plasmid DNA. CAG-driven, Flp-dependent mNeonGreen expression. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Chan et al Nat Neurosci. 2017 Aug;20(8):1172-1179.

Jan. 6, 2022

Academic Institutions and Nonprofits only

#176752-AAV5

Ready-to-use AAV5 particles produced from AAV-CamKIIa-jGCaMP8s-WPRE (#176752). In addition to the viral particles, you will also receive purified AAV-CamKIIa-jGCaMP8s-WPRE plasmid DNA. CamKIIa-driven expression of calcium sensor GCaMP8s (more sensitive). These AAV preparations are suitable purity for injection into animals.

Loren Looger

Sept. 27, 2024

Academic Institutions and Nonprofits only

#179529-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-4mtGCaMP6f-DIO (#179529). In addition to the viral particles, you will also receive purified pAAV-EF1a-4mtGCaMP6f-DIO plasmid DNA. EF1a-driven, Cre-dependent expression of mitochondria-targeted GCaMP8f. These AAV preparations are suitable purity for injection into animals.

Maarten Kole

Kole et al Nat Commun. 2022 Dec 9;13(1):7598. doi:

Feb. 6, 2026

Academic Institutions and Nonprofits only

#176267-AAV1

Ready-to-use AAV1 particles produced from pAAV-FLEX-P301L Tau (#176267). In addition to the viral particles, you will also receive purified pAAV-FLEX-P301L Tau plasmid DNA. EF1a-driven, Cre-dependent expression of human 2N4R microtubule-associated protein tau with P301L mutation. These AAV preparations are suitable purity for injection into animals.

Tsuneya Ikezu

You et al Neuroscience. 2019 Dec 1;422:65-74. doi:

Aug. 7, 2025

Academic Institutions and Nonprofits only

#50465-AAV5.T

Ready-to-use AAV5 trial size particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

June 12, 2019

Academic Institutions and Nonprofits only

#75033-AAV1

Ready-to-use AAV1 particles produced from pAAV CD68-hM4D(Gi)-mCherry (#75033). In addition to the viral particles, you will also receive purified pAAV CD68-hM4D(Gi)-mCherry plasmid DNA. CD68-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced microglial inhibition. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Grace et al Proc Natl Acad Sci U S A. 2016 Jun 14;11

March 27, 2019

Academic Institutions and Nonprofits only

#35499-AAV9

Ready-to-use AAV9 particles produced from pAAV-CaMKIIa-C1V1 (t/t)-TS-EYFP (#35499). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-C1V1 (t/t)-TS-EYFP plasmid DNA. CaMKIIa-driven, C1V1 (t/t) fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Yizhar et al Nature. 2011 Jul 27;477(7363):171-8. doi

April 6, 2018

Academic Institutions and Nonprofits only

#135630-AAV9

Ready-to-use AAV9 particles produced from pAAV-S5E2-dTom-nlsdTom (#135630). In addition to the viral particles, you will also receive purified pAAV-S5E2-dTom-nlsdTom plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Nov. 29, 2021

Academic Institutions and Nonprofits only

#119036-AAV1

Ready-to-use AAV1 particles produced from pAAV-hsyn-flex-Voltron-ST (#119036). In addition to the viral particles, you will also receive purified pAAV-hsyn-flex-Voltron-ST plasmid DNA. Synapsin-driven, cre-dependent expression of genetically encoded fluorescent voltage indicator Voltron1 with a soma-targeting sequence. These AAV preparations are suitable purity for injection into animals.

Eric Schreiter

Abdelfattah et al Science. 2019 Aug 1. pii: science.aav641

April 10, 2019

Academic Institutions and Nonprofits only

#75469-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-Flp-DOG-NW (#75469). In addition to the viral particles, you will also receive purified pAAV-EF1a-Flp-DOG-NW plasmid DNA. EF1a-driven expression of Flp recombinase dependent on GFP (Flp-DOG); to be coinjected with GFP (or for use with transgenic GFP animals). These AAV preparations are suitable purity for injection into animals.

Connie Cepko

Tang et al Elife. 2016 May 20;5. pii: e15312. doi:

Feb. 19, 2020

Academic Institutions and Nonprofits only

#198513-AAV5

Ready-to-use AAV5 particles produced from pAAV_hSyn-PdCO-EGFP-WPRE (#198513). In addition to the viral particles, you will also receive purified pAAV_hSyn-PdCO-EGFP-WPRE plasmid DNA. Synapsin-driven expression of the optimized opsin PdCO in frame with EGFP. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

April 10, 2024

Academic Institutions and Nonprofits only

#179256-AAV1

Ready-to-use AAV1 particles produced from AAV-CAG-jGCaMP8s-WPRE (#179256). In addition to the viral particles, you will also receive purified AAV-CAG-jGCaMP8s-WPRE plasmid DNA. CAG-driven expression of calcium sensor GCaMP8s. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Jan. 24, 2024

Academic Institutions and Nonprofits only

#135631-AAV9

Ready-to-use AAV9 particles produced from pAAV-S5E2-GFP-fGFP (#135631). In addition to the viral particles, you will also receive purified pAAV-S5E2-GFP-fGFP plasmid DNA. Bicistronic expression of GFP and membrane-targeted GFP under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Sept. 27, 2023

Academic Institutions and Nonprofits only

#37825-AAV6.T

Ready-to-use AAV6 trial size particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

July 16, 2025

Academic Institutions and Nonprofits only